Effect and safety of supplementation of Lactobacilli powder to the patients with atopic dermatitis accompanied by food allergy

Effect and safety of supplementation of Lactobacilli powder to the patients with atopic dermatitis accompanied by food allergy - Supplementation of Lactobacilli powder to the patients with atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006209

Enrollment

Registered

2011-08-22

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Supplementation of dry powder containing 20 mg of Lactobacillus acidophils L-92 once a day for 24 weeks. Supplementation of dry powder containing 0.2 mg of Lactobacillus acidophils L-92 once a day for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Definitive atopic dermatitis which requires daily topical corticosteroid ointment. 2. Undergoing the standard treatment and skin care based on the Japanese guideline for atopic dermatitis. 3. Associated with food allergy, or avoiding some food due to the high level of specific IgE test. 4. NOT taking probiotic food or drugs daily to improve the intestinal flora. 5. NOT associated with bacterial or fungal skin infection, or any other skin diseases.

Exclusion criteria

Exclusion criteria: 1. Suspected NOT to be able to take the powder food daily. 2. Clinical history of severe anaphylaxis caused by the small amount of milk product. 3. Any severe complications such as diabetes, gastrointestinal, renal, or heart diseases. 4. Clinical history of hypersensitivity to steroid ointment, skin moisturizer or the test food. 5. Undergoing or planning any other intervention study. 6. Any other inappropriate conditions judged by the participant doctors.

Design outcomes

Primary

Measure	Time frame
Decrease in SCORAD index after 24 week	—

Secondary

Measure	Time frame
QOL, Dose of topical corticosteroid, intestinal flora, eosinophils, IgE, LDH, AST, ALT, TARC after 24 weeks	—

Countries

Japan

Contacts

Public ContactKomei Ito

Aichi Children's Health and Medical Center Department of Allergy

0562-43-0500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026